Komori
Ono Pharmaceutical (4528) · PolicyAdvancedLatest Governance (2026-09-30): "Restated"

Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers

First written in FY2016. 6 of 12 entries say "Advanced", first in FY2018. Latest entry: 2026-09-30.

12entries
11years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2017AdvancedFY2018 – FY20252016: 120162017: 120172018: 120182019: 020192020: 120202021: 020212022: 020222023: 120232024: 120242025: 120252026: 52026
Same theme, other companies

25 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 71 companies compared. The sentences above are computed from all 71.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The main matters considered by the Board of Directors during the fiscal year under review were as follows: progress reports on the growth strategy, discussed under the themes of strengthening the pipeline, expanding and accelerating the global business, expanding business domains, the management platform supporting the growth strategy, and corporate transformation through digital and IT; group finance-related matters; expense budgets; and analyses of the cost of capital, capital profitability and market valuation.」

    The Board of Directors continued to deliberate on the growth strategy by theme, and also considered group finance, the cost of capital, capital profitability, market valuation, cybersecurity and other matters.
  2. FY2025AdvancedAnnual report

    「The main matters considered by the Board of Directors during the fiscal year under review were as follows: progress reports on the growth strategy, discussed under the themes of expanding and accelerating the global business, strengthening the pipeline, expanding business domains, the management platform supporting the growth strategy, and corporate transformation through digital and IT; materialities; acquisitions; post-acquisition management, operations and integration policies; and analyses of the cost of capital, capital profitability and market valuation.」

    The Board of Directors met 12 times and deliberated by theme on 4 growth strategies, intangible assets, post-acquisition management and integration policies, the cost of capital and other matters.
  3. FY2024AdvancedAnnual report

    「The main matters deliberated by the Board of Directors during the fiscal year under review were as follows: progress reports on management strategy, sustainability and growth strategy, reported under the themes of strengthening the pipeline and accelerating global development, realizing direct sales in Europe and the United States, expanding business domains, the management platform supporting the growth strategy, and corporate transformation through digital and IT; and the acquisition of Deciphera Pharmaceuticals, Inc.」

    The Board of Directors deliberated on 4 growth strategies, intangible assets and the acquisition of Deciphera, among other matters, making its oversight of the growth strategy and acquisition more specific.
  4. FY2023AdvancedAnnual report

    「The main matters deliberated during the fiscal year under review were as follows: progress reports on management strategy, sustainability and growth strategy; formulation of the Global Human Rights Policy; reports on the development and operation of the internal control system; reports on activities to strengthen the compliance structure; risk management reports; and individual reviews of cross-shareholdings.」

    The Board of Directors continued to deliberate on growth strategy, sustainability, human rights, internal controls, risk and cross-shareholdings, and met 12 times during the fiscal year under review.
  5. FY2020AdvancedAnnual report

    「We have invited 3 outside directors with experience in corporate management and specialized knowledge and extensive experience, with the objectives of maintaining and improving the soundness of management and the accuracy of business execution and strengthening oversight. The outside directors play an important role in corporate governance decision-making, including the nomination of candidates for directors and corporate auditors and determining compensation for directors and others, as key members of the meetings reviewing proposals for officer appointments and officer compensation.」

    The oversight structure has been described in specific terms, with 3 outside directors serving as key members of the meetings reviewing officer appointments and compensation and participating in nomination and compensation decisions.
  6. FY2018AdvancedAnnual report

    「We are further enhancing corporate governance by inviting 3 outside directors with experience in corporate management and specialized knowledge and extensive experience, with the objectives of maintaining and improving the soundness of management and the accuracy of business execution and strengthening oversight.」

    The number of outside directors increased from the 2 previously stated to 3, making the strengthening of oversight by outside officers more specific.
  7. FY2017RestatedAnnual report

    「To enhance corporate value, we believe that important management issues include increasing transparency in management and strengthening management control functions, in addition to complying with laws and regulations.」

    The policy of strengthening transparency and oversight through a company with a board of company auditors, the Board of Directors and Board of Company Auditors, 2 outside directors, and the Management Strategy Meeting has been reaffirmed.
  8. FY2016First statedAnnual report

    「To enhance corporate value, we believe that important management issues include increasing transparency in management and strengthening management control functions, in addition to complying with laws and regulations.」

    The policy is to strengthen transparency and oversight through a company with a board of company auditors, 2 outside directors, outside corporate auditors and the Management Strategy Meeting.
Moved together

"Expansion of the development pipeline and continued launches of new drugs" moved the same way as this thread, in the same document, in 6 of its 12 moves.

665555★123456
  1. ★This thread
  2. 1Expansion of the development pipeline and continued launches of new drugs6×
  3. 2Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures6×
  4. 3In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials5×
  5. 4Global business expansion and international launches5×
  6. 5Expansion of Opdivo’s indications and progress in international development and sales5×
  7. 6Holding Shares to Maintain and Strengthen Business Relationships5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the Governance of 2026-09-30: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori